ROMLUSEVIMAB

UNII:	SM01RRU9KK
Formula:
Preferred Substance Name:	ROMLUSEVIMAB
GSRS Full Record:	SM01RRU9KK i

2509447-08-7
BRII198
BRII-198
IMMUNOGLOBULIN G1-LAMBDA2, ANTI-(SEVERE ACUTE RESPIRATORYSYNDROME CORONAVIRUS 2 (SARS-COV-2) SPIKE (S) GLYCOPROTEIN,RECEPTOR BINDING DOMAIN (RBD)), HOMO SAPIENS MONOCLONALANTIBODY
IMMUNOGLOBULIN G1-LAMBDA2, ANTI-SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-COV) (SPIKE GLYCOPROTEIN (PEPLOMER PROTEIN)); HOMO SAPIENS MONOCLONAL ANTIBODY; .GAMMA.1 HEAVY CHAIN HOMO SAPIENS (1-448) (VH (HOMO SAPIENS IGHV7-4-1*02 (96%)-(IGHD)-IGHJ6*01) (8.8.12) (1-119)-HOMO SAPIENS IGHG1*01 (CH2(M22>Y(254), S24>T(256), T26>E(258)), CH3(K107>DEL(449))) (120-448)) (222-213')-DISULFIDE WITH .LAMBDA.2 LIGHT CHAIN HOMO SAPIENS (1'-214') (V-LAMBDA (HOMO SAPIENS IGLV3-21*01 (98%)-IGLJ2*01)(6.3.11) (1'-108')-HOMO SAPIENS IGLC2*01 (109'-214')), DIMER (228-228'':231-231'')-BISDISULFIDE, PRODUCED IN CHO-K1 CELL LINE, GLYCOFORM ALFA
ROMLUSEVIMAB [INN]
ROMLUSEVIMAB [USAN]
ROMLUSEVIMAB [WHO-DD]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

ROMLUSEVIMAB

Synonyms and Mappings

Resources